# ADAPY catalysts: Adaptimmune Therapeutics PLC PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/adapy/catalysts

> Adaptimmune Therapeutics PLC (ADAPY) has no upcoming catalysts in this calendar. The latest recorded is the Adaptimmune Therapeutics PLC earnings report, August 13, 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Adaptimmune Therapeutics PLC |
| Ticker | ADAPY (OTC) |
| SEC CIK | 1621227 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/adapy |

## Cash runway

Cash $26.1M as of 2025-06-30; quarterly burn $34.8M; about 2.2 months of runway at that rate (XBRL company facts, accession 0001558370-25-011307).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| August 1, 2024 | [TECELRA (afamitresgene autoleucel) FDA approval](https://sec-api.dev/pdufa/afamitresgene-autoleucel) | ADAPY | advanced synovial sarcoma and | completed, approved | "The product revenue has increased due to product sales commencing following the FDA approval of TECELRA on August 1, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1621227/000155837025011304/adap-20250813xex99d1.htm)) |
| Aug 2024 | [Famitresgene autoleucel FDA approval](https://sec-api.dev/pdufa/famitresgene-autoleucel) | ADAPY | unresectable/metastatic synovial sarcoma | completed, approved | "In August 2024 we received accelerated approval from the FDA for TECELRA (famitresgene autoleucel or afami-cel) for adults with unresectable/metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02 eligible, and whose tumor expresses MAGE-A4 as determined by FDA-approved diagnostics." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1621227/000155837025003544/adap-20241231x10k.htm)) |
| November 13, 2024 | [Adaptimmune Therapeutics PLC earnings report](https://sec-api.dev/companies/adapy/catalysts) | ADAPY |  | completed | "PHILADELPHIA, PA. and OXFORD, UK, November 13, 2024 - Adaptimmune Therapeutics plc (Nasdaq: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today reports financial results and business updates for the third quarter ended September 30, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1621227/000155837024015525/adap-20241113xex99d1.htm)) |
| December 31, 2024 | [TECELRA (afamitresgene autoleucel) FDA approval](https://sec-api.dev/pdufa/afamitresgene-autoleucel) | ADAPY |  | completed, approved | "As of December 31, 2024, the Company's only commercially approved product was TECELRA® ("TECELRA"), which was approved by the FDA on August 1, 2024." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1621227/000155837025003544/adap-20241231x10k.htm)) |
| May 13, 2025 | [Adaptimmune Therapeutics PLC earnings report](https://sec-api.dev/companies/adapy/catalysts) | ADAPY |  | completed | "Adaptimmune Reports Q1 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1621227/000155837025007493/adap-20250513xex99d1.htm)) |
| August 13, 2025 | [Adaptimmune Therapeutics PLC earnings report](https://sec-api.dev/companies/adapy/catalysts) | ADAPY |  | completed | "Adaptimmune Reports Q2 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1621227/000155837025011304/adap-20250813xex99d1.htm)) |

## Drugs

- [TECELRA (afamitresgene autoleucel)](https://sec-api.dev/pdufa/afamitresgene-autoleucel): advanced synovial sarcoma and, advanced mage-a4+ synovial sarcoma in adults with certain hla types, solid tumor cancer approved
- [Famitresgene autoleucel](https://sec-api.dev/pdufa/famitresgene-autoleucel): unresectable/metastatic synovial sarcoma

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/adapy/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ADAPY catalysts: Adaptimmune Therapeutics PLC PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/adapy/catalysts

```bibtex
@misc{secapidev_companies_adapy_catalysts_20261116,
  title        = {ADAPY catalysts: Adaptimmune Therapeutics PLC PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/adapy/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_adapy_catalysts_20261116","title":"ADAPY catalysts: Adaptimmune Therapeutics PLC PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/adapy/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
